U.S. markets close in 46 minutes

Cerus Corporation (CERS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.21-0.02 (-0.28%)
As of 3:14PM EST. Market open.

Cerus Corporation

1220 Concord Avenue
Concord, CA 94520
United States

Full Time Employees254

Key Executives

NameTitlePayExercisedYear Born
Mr. William M. GreenmanPres, CEO & Director1.11MN/A1967
Dr. Laurence M. CorashCo-Founder & Chief Scientific Officer646.48kN/A1944
Mr. Kevin D. GreenVP of Fin. & CFO608.68k44.46k1972
Mr. Vivek K. JayaramanChief Operating Officer671.02kN/A1975
Dr. Richard J. BenjaminChief Medical Officer620.21kN/A1960
Ms. Lori L. RollVP of Admin. & Corp. Sec.N/AN/AN/A
Mr. Timothy J. LeeInvestor Relations DirectorN/AN/AN/A
Ms. Chrystal N. MenardChief Legal Officer & Gen. CounselN/AN/A1971
Lainie CortenVP of Global MarketingN/AN/AN/A
Ms. Carol M. MooreSr. VP of Regulatory Affairs, Quality & ClinicalN/AN/A1950
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company has a collaboration with the National Trauma Institute to supply Intercept plasma for use in the plasma resuscitation without lung injury (PROpOLIs) clinical study. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Corporate Governance

Cerus Corporation’s ISS Governance QualityScore as of December 1, 2020 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.